Overview

Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Status:
Recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Viracta Therapeutics, Inc.

Treatments:

Pembrolizumab
Valganciclovir